Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37.
Tokumaru. Sho S; Sayama. Koji K; Shirakata. Yuji Y; Komatsuzawa. Hitoshi H; Ouhara. Kazuhisa K; Hanakawa. Yasushi Y; Yahata. Yoko Y; Dai. Xiuju X; Tohyama. Mikiko M; Nagai. Hiroshi H; Yang. Lujun L; Higashiyama. Shigeki S; Yoshimura. Akihiko A; Sugai. Motoyuki M; Hashimoto. Koji K
Key Findings
- LL-37 at 1 µg/ml strongly stimulates keratinocyte migration in vitro
- The effect depends on EGFR transactivation via heparin‑binding EGF
- STAT3 activation is required downstream, and SOCS proteins can shut the response off
Practical Outcomes
- LL-37 shows promise as a topical agent to speed up skin wound healing, but the study only used cell cultures and didn’t define safe human doses. Biohackers should wait for clinical trials before trying LL-37 products, and any future creams will likely need to deliver the peptide at concentrations similar to the lab findings.
Summary
The antimicrobial peptide LL-37 helps skin cells move to close wounds by turning on a growth‑factor receptor (EGFR) and downstream signals. This effect was seen in lab dishes at a concentration of about 1 µg/ml and can be blocked by drugs that stop EGFR or its signaling pathways.
Abstract
The closure of skin wounds is essential for resistance against microbial pathogens, and keratinocyte migration is an important step in skin wound healing. Cathelicidin hCAP18/LL-37 is an innate antimicrobial peptide that is expressed in the skin and acts to eliminate microbial pathogens. Because hCAP18/LL-37 is up-regulated at skin wound sites, we hypothesized that LL-37 induces keratinocyte migration. In this study, we found that 1 microg/ml LL-37 induced the maximum level of keratinocyte migration in the Boyden chamber assay. In addition, LL-37 phosphorylated the epidermal growth factor receptor (EGFR) after 10 min, which suggests that LL-37-induced keratinocyte migration occurs via EGFR transactivation. To test this assumption, we used inhibitors that block the sequential steps of EGFR transactivation, such as OSU8-1, CRM197, anti-EGFR no. 225 Ab, and AG1478. All of these inhibitors completely blocked LL-37-induced keratinocyte migration, which indicates that migration occurs via HB-EGF-mediated EGFR transactivation. Furthermore, CRM197, anti-EGFR no. 225, and AG1478 blocked the LL-37-induced phosphorylation of STAT3, and transfection with a dominant-negative mutant of STAT3 abolished LL-37-induced keratinocyte migration, indicating the involvement of the STAT3 pathway downstream of EGFR transactivation. Finally, we tested whether the suppressor of cytokine signaling (SOCS)/cytokine-inducible Src homology 2-containing protein (CIS) family of negative regulators of STAT3 regulates LL-37-induced keratinocyte migration. Transfection with SOCS1/Jak2 binding protein or SOCS3/CIS3 almost completely abolished LL-37-induced keratinocyte migration. In conclusion, LL-37 induces keratinocyte migration via heparin-binding-EGF-mediated transactivation of EGFR, and SOCS1/Jak 2 binding and SOCS3/CIS3 negatively regulate this migration. The results of this study suggest that LL-37 closes skin wounds by the induction of keratinocyte migration.
Study Information
pubmed
2005
2005-10-01T00:00:00.000Z
10.4049/jimmunol.175.7.4662
350
57